1. Home
  2. UVV vs XERS Comparison

UVV vs XERS Comparison

Compare UVV & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Corporation

UVV

Universal Corporation

HOLD

Current Price

$53.15

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$5.46

Market Cap

965.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UVV
XERS
Founded
1886
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
965.6M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
UVV
XERS
Price
$53.15
$5.46
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$10.43
AVG Volume (30 Days)
171.6K
2.1M
Earning Date
05-11-2026
05-18-2026
Dividend Yield
6.22%
N/A
EPS Growth
N/A
100.00
EPS
3.02
N/A
Revenue
$2,922,924,000.00
$49,590,000.00
Revenue This Year
$0.67
$28.65
Revenue Next Year
$0.10
$18.33
P/E Ratio
$17.46
N/A
Revenue Growth
7.40
142.67
52 Week Low
$49.96
$3.81
52 Week High
$67.33
$10.08

Technical Indicators

Market Signals
Indicator
UVV
XERS
Relative Strength Index (RSI) 47.11 26.31
Support Level $51.72 $4.30
Resistance Level $54.01 $5.49
Average True Range (ATR) 0.88 0.34
MACD -0.02 -0.06
Stochastic Oscillator 51.02 3.62

Price Performance

Historical Comparison
UVV
XERS

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: